Many physicians wrinkle their noses at the idea of selling products in the office. But what about offering patients educational materials at the time of diagnosis?
In our clinics we face practical decisions every day. Multiple competing drugs are often available for any particular problem. Glaucoma treatment options are especially numerous. A little math can easily demonstrate the complexity of glaucoma treatment options.
As allergy season is approaching, it is important for the physician to understand that ocular allergy is only a component of a broader condition that many times involves the nose and sinuses.
San Antonio, TX-A treatment for seasonal allergic conjunctivitis, pemirolast potassium 0.1% ophthalmic solution (Alamast, Santen Inc., Napa, CA), was shown to be more comfortable for patients and equally effective when used twice a day during ragweed season when compared with nedocromil sodium 2% ophthalmic solution (Alocril, Allergan, Irvine, CA). These two drugs are the two latest mast-cell stabilizers that have become commercially available to treat ocular allergies.
London, Ontario, Canada-Patients with seasonal allergic conjunctivitis that includes ocular symptoms may benefit from a combination of fexofenadine HCl capsules (Allegra, Aventis Pharmaceuticals Inc., Bridgewater, NJ) supplemented with the ophthalmic solution of nedocromil sodium 2% (Alocril, Allergan, Irvine, CA).
Ocular allergies are a major source of discomfort and annoyance. Allergic symptoms often interfere with such common activities as reading, sports, or working on a computer. Greater public awareness of allergic conditions and less tolerance of their signs and symptoms are driving the need for better diagnosis and treatment.
San Francisco-Levofloxacin (Quixin, Santen)-the new kid in the fluoroquinolone family-is less likely to encounter resistant strains of bacteria than the two older members of that antibiotic family, ofloxacin (Ocuflox, Allergan) and ciprofloxacin (Ciloxan, Alcon), according to David Hwang, MD.
Since the release of the topical beta-blocker timolol maleate (Timoptic, Merck) some 2 decades ago, glaucoma patients have been the beneficiaries of a cascade of new IOP-lowering pharmaceuticals.
Portland, OR-Hormone replacement therapy (HRT) does not appear to alter the incidence of dry eye symptoms or physiologic dry eye in women prior to or during menopause, according to Oregon researchers.
When faced with a patient having lash or eyebrow hair loss, a careful history searching for clues is help-ful. Hair loss involving the eyelashes or eye-brow area may result from several conditions including skin diseases, drug side effects, endocrine abnormalities, metabolic abnormalities, inflammation, toxins, radiation effects, systemic diseases, infection, and trauma.